Welcome to our dedicated page for Materialise SEC filings (Ticker: MTLS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Materialise NV (MTLS) SEC filings page brings together the company’s official disclosures as a foreign private issuer under the Securities Exchange Act of 1934. Materialise files Form 6‑K reports to provide English‑language versions of press releases, financial results, and other information that it makes public in Belgium or through other regulatory channels.
In its 6‑K filings, Materialise reports detailed quarterly financial results, including revenue by segment for Materialise Medical, Materialise Software, and Materialise Manufacturing, gross profit, operating result, net profit, cash and debt positions, and non‑IFRS measures such as EBIT, EBITDA, Adjusted EBIT, and Adjusted EBITDA. These filings also explain how non‑IFRS metrics are calculated and why management uses them to evaluate performance.
Beyond earnings, Materialise uses 6‑K reports to disclose capital markets and governance developments. Recent filings describe the company’s additional listing of its ordinary shares on Euronext Brussels, the publication of a listing prospectus, and shareholder approvals of a new text of the articles of association, including the introduction of double voting rights for certain shares. Other filings outline an up to EUR 30 million ADS buyback program over Nasdaq, subject to specific conditions, and provide information about extraordinary general shareholders’ meetings and proposed amendments to the articles of association.
On Stock Titan, these SEC filings are updated in near real time from EDGAR and are paired with AI‑powered summaries that highlight the main points of each document. Investors can quickly see what changed in the latest 6‑K, how segment performance evolved, and what new authorizations or listings have been announced. For deeper analysis, users can review the full text of the filings, including financial tables and explanatory notes, while using AI insights to navigate complex financial and legal language more efficiently.
Materialise NV reports progress on its ongoing share buy-back program of up to EUR 30 million. During the week from 23 to 27 March 2026, the company repurchased 50,994 shares at an average price of 4.26 EUR per share, for a total of 217,478 EUR.
All purchases were executed on Nasdaq through the central order book, with no cross or block trades. Since the program started on 26 January 2026, Materialise has bought back 499,478 shares for 2,257,288 EUR (2,663,137 USD), equal to 0.8% of its total shares outstanding, and now holds these shares in treasury.
Materialise NV reports further progress on its share buy-back program of up to EUR 30 million. Between 16 and 20 March 2026, the company repurchased 46,665 shares at an average price of 4.39 EUR, for a total of 204,627 EUR.
Since the program began on 26 January 2026, Materialise has bought back 448,484 shares for 2,039,810 EUR (approximately 2,411,424 USD), representing about 0.8% of total shares outstanding. Materialise now holds 448,484 of its own shares.
Materialise NV reports progress on its ongoing share buyback program of up to EUR 30 million. Between 9 and 13 March 2026, the company repurchased 52,701 shares on Nasdaq at an average price of EUR 4.62, for a total of EUR 243,690 (USD 281,523). Since the program began on 26 January 2026, Materialise has bought back 401,819 shares for EUR 1,835,183 (USD 2,175,722), equal to 0.7% of total shares outstanding, which it now holds as treasury shares.
Materialise NV reports progress on its previously announced share buy-back program of up to EUR 30 million. From 2 March 2026 through 6 March 2026, the company repurchased 36,121 shares at an average price of EUR 4.49, for a total of EUR 162,264.
Since the start of the program on 26 January 2026, Materialise has bought back 349,118 shares for EUR 1,591,493 (USD 1,894,199), representing 0.6% of total shares outstanding. Materialise now holds these 349,118 shares in treasury.
Materialise NV reports progress on its previously announced share buy-back program of up to EUR 30 million. During the week from 23 to 27 February 2026, the company repurchased 79,791 shares at an average price of 4.30 EUR, for a total of 342,715 EUR.
Since the program began on 26 January 2026, Materialise has bought back 312,997 shares for 1,429,229 EUR (approximately 1,705,609 USD), representing about 0.5% of its total shares outstanding, which the company now holds as treasury shares.
Materialise NV reports progress on its previously announced share buy-back program of up to EUR 30 million. Between 16 and 20 February 2026, the company repurchased 69,861 shares at an average price of 4.76 EUR per share, for a total of 332,435 EUR.
All purchases during this week were executed on NASDAQ and no shares were bought via cross or block trades. Since the program started on 26 January 2026, Materialise has bought back 233,206 shares for 1,086,514 EUR (1,286,818 USD), equal to 0.4% of total shares outstanding.
Materialise NV reported stronger fourth-quarter 2025 results, with revenue up 6.8% to 70,164 kEUR and net profit rising to 6,206 kEUR from 2,907 kEUR. Gross margin improved to 58.1%, while operating profit swung to 3,111 kEUR from a loss a year earlier.
Growth was driven by the Materialise Medical segment, whose Q4 revenue rose 16.3% and Adjusted EBITDA margin reached 35.2%. For full year 2025, revenue was broadly stable at 267,633 kEUR, but net profit declined to 7,716 kEUR from 13,406 kEUR, mainly due to weaker financial result and foreign exchange impacts. Cash and cash equivalents increased to 133,918 kEUR, and Adjusted EBITDA margin improved slightly to 12.1%.
Materialise NV reported higher profitability for Q4 2025 and modest full-year growth, led by strong performance in its Medical segment. Fourth-quarter revenue rose 6.8% to 70,164 kEUR and net profit more than doubled to 6,206 kEUR, supported by a jump in adjusted EBITDA to 9,524 kEUR.
For full year 2025, revenue was broadly flat at 267,633 kEUR, but adjusted EBITDA edged up to 32,386 kEUR and adjusted EBIT to 10,601 kEUR. Medical revenue grew 15.4% with a 32.0% adjusted EBITDA margin, while Software revenue declined and Manufacturing contracted, producing a negative margin.
The company ended 2025 with 133,918 kEUR of cash and cash equivalents and a net cash position of 70,805 kEUR. For 2026, it guides revenue to 273,000–283,000 kEUR and expects adjusted EBIT between 10,000 and 12,000 kEUR, driven by continued Medical growth and ongoing Manufacturing restructuring.
Materialise NV reported progress on its previously announced share buyback program. During the period from 9 to 13 February 2026, the company repurchased 52,222 shares at an average price of 4.67 EUR, for a total of 243,734 EUR, via Nasdaq’s central order book.
Since the program started on 26 January 2026, Materialise has bought back 163,345 shares for 754,080 EUR (895,012 USD), equal to 0.3% of its total shares outstanding. The company now holds 163,345 of its own shares and plans to keep publishing weekly updates on its investor website.
Materialise NV reports progress on its share buy-back program of up to EUR 30 million. From 2 to 6 February 2026, the company repurchased 66,945 shares on Nasdaq at an average price of 4.54 EUR per share, for a total of 303,785 EUR (358,738 USD).
Since the program started on 26 January 2026, Materialise has bought back 111,123 shares for 510,346 EUR (605,421 USD), equal to 0.2% of total shares outstanding. The company now holds 111,123 own shares and publishes weekly updates on its investor website.